Connection

Andrea Isidori to Phosphodiesterase 5 Inhibitors

Back to Details
This is a "connection" page, showing publications Andrea Isidori has written about Phosphodiesterase 5 Inhibitors.
Andrea Isidori
Connection Strength
1.883
Phosphodiesterase 5 Inhibitors
  1. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology. 2021 01; 9(1):33-38.
    View in: PubMed
    Score: 0.785
  2. PDE5 Inhibition Stimulates Tie2-Expressing Monocytes and Angiopoietin-1 Restoring Angiogenic Homeostasis in Diabetes. J Clin Endocrinol Metab. 2019 07 01; 104(7):2623-2636.
    View in: PubMed
    Score: 0.732
  3. Chronic phosphodiesterase type 5 inhibition has beneficial effects on subcutaneous adipose tissue plasticity in type 2 diabetic mice. J Cell Physiol. 2018 11; 233(11):8411-8417.
    View in: PubMed
    Score: 0.170
  4. Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Sci Rep. 2017 03 15; 7:44584.
    View in: PubMed
    Score: 0.156
  5. Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line. J Cell Physiol. 2018 Jan; 233(1):325-337.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.